Ionis Pharmaceuticals (IONS) - Rasio rega marang prakiraan pendapatan
Ionis Pharmaceuticals (IONS) focuses on developing innovative RNA-based therapies for heart and brain diseases, leveraging partners to mitigate risks. The company implements ESG principles by optimizing waste disposal and research ethics. The automation of oligonucleotide synthesis via robotics accelerates preclinical testing. The company's expected P/S ratio clearly demonstrates the link between market capitalization and revenue forecasts, while 4.70 captures the current state of the parameter.
IONS (Isis Pharmaceuticals): rincian analitis lan laporan miturut indikator
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- indikator nilai buku ekuitas:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Ionis Pharmaceuticals|IONS - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Ionis Pharmaceuticals|IONS - Gunggung utang perusahaan|Utang marang nilai buku Isis Pharmaceuticals|IONS - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Ionis|Rasio cepet ionispharma.com
- rincian asil keuangan lan kelipatan valuasi:
IONS - Penghasilan resik|Proyeksi bathi mangsa ngarep Ionis Pharmaceuticals|IONS - Pangali P/E|Rega marang bathi mangsa ngarep Ionis Pharma|IONS - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Isis Pharmaceuticals|IONS - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Ionis|IONS - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan ionispharma.com|IONS - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Ionis Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:Ionis (IONS)
Investors are evaluating Ionis Pharmaceuticals (IONS) through the lens of oligonucleotide synthesis robotization efficiency, which accelerates time-to-market for drugs. The forward P/S ratio compares the company's current market value with expected future sales volumes, determining the premium paid for upcoming revenue growth. Analyzing the projected P/S ratio allows for an objective assessment of the asset's fundamental attractiveness and identifies the long-term consensus point during periods of volatility.
Perusahaan pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|Rega forward marang dodolan QGEN|RGEN - Rasio rega marang prakiraan pendapatan|Avidity Corp (RNA) - Multiplikator forward rega marang pendapatan|CRSP: Multiplikator Forward P/S|genedx.com (WGS) - Multiplikator Forward P/S|RARE (Ultragenyx) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Beam Therapeutics Inc (BEAM)|Multiplikator Forward P/S SRPT|TWST - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|10x Genomics, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S intelliatx.com NTLA|STOK: Multiplikator forward rega marang pendapatan|BioLife Solutions Inc - Rasio rega marang pendapatan sing dikarepake|WVE: Multiplikator Forward P/S|MAZE - Rasio kapitalisasi marang dodolan sing dikarepake|SION (Sionna Therapeutics Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan primemedicine.com (PRME)|Multiplikator Forward P/S TSHA|Multiplikator Forward P/S uniQure NV (QURE)|Rasio rega marang prakiraan pendapatan MeiraGTx PLC MGTX|REGENXBIO Corp - Rasio rega marang prakiraan pendapatan|SLDB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake ocugen.com OCGN|PACB: Multiplikator Forward P/S|BNTC - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Design Pharma|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Rocket Corp RCKT|Rasio rega marang prakiraan pendapatan 4D Molecular Therapeutics (FDMT)|lexeotx.com - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Korro Bio KRRO|Rasio kapitalisasi marang dodolan sing dikarepake Editas Medicine Inc (EDIT)|Silence Therapeutics Inc. - Multiplikator Forward P/S|PRQR (ProQR Therapeutics N.V.) - Kapitalisasi marang prakiraan pendapatan|codexis.com (CDXS) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan SGMO|NAUT (Nautilus Biotechnology, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Metagenomi Inc.|Multiplikator Forward P/S DTIL|Rasio kapitalisasi marang dodolan sing dikarepake generationbio.com|Rasio rega marang prakiraan pendapatan Boundless Bio, Inc. BOLD|Exicure Inc. (XCUR) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|IMNN - Rasio rega marang prakiraan pendapatan|PHIO (Phio Pharmaceuticals) - Kapitalisasi marang prakiraan pendapatan|MBIO: Multiplikator Forward P/S|RNAZ - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Bionano Genomics Inc.|adnas.com (APDN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan BLUE (bluebird bio)|IPA (immunoprecise.com) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Omega OMGA|OMIC (Singular Genomics Corp) - Rega mangsa ngarep marang pendapatan|Regulus Therapeutics - Multiplikator Forward P/S|Rega forward marang dodolan SYRS (syros.com)|TBIO: Multiplikator Forward P/S|TRACON Pharmaceuticals Inc. (TCON) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Unity Bio
